Dr. Mell Discusses Flaws in Risk Stratification for Head and Neck Cancer

Video

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses flaws in the current model of risk stratification for patients with head and neck cancer.

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses flaws in the current model of risk stratification for patients with head and neck cancer.

The dominant paradigm used to risk-stratify patients with head and neck cancer is fundamentally flawed, says Mell. The current models tend to focus on 1 endpoint, or class of endpoints, called event-free survival—most commonly overall survival. This is an unambiguous endpoint, making it simple to quantify. Mell says that although it is a desirable endpoint to know, it does not account for patients who have an appreciable risk of dying from something other than cancer.

Mell claims that these current models fail because they treat death from cancer equally to a death not from cancer. This results in a patient with very advanced cancer being put in the same category as a patient with cancer who is at a high-risk for death due to separate health problems. These patients need different treatment regimens, and nothing will be solved if these events are not separated, Mell says. Risk stratification schemes should not focus solely on the tumors, because at best, they are only explaining part of the problem.

Related Videos
Nikhil A. Gopal, MD
Kara N. Maxwell, MD, PhD
Ruben Olivares, MD
Scott Kopetz, MD, PhD, FACP
Rita Nanda, MD
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Lauren E. Nye, MD, breast medical oncologist, clinical medical director, Breast Cancer Prevention, the University of Kansas Cancer Center
Joseph G. Jurcic, MD
Zeynep Eroglu, MD
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute